Key facts
- This page summarizes Mark Arnold Hagler's Form 4 filing for NovaBridge Biosciences (NBP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2026, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Additional SEC filing notes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
Footnote F2
Reported securities are represented by 20,000 ADSs.
Footnote F3
The price reported in Column 4 represents the converted sales price of the ADSs of $0.79.
Footnote F4
Reported securities are represented by 80,000 ADSs.
Footnote F5
The price reported in Column 4 represents the converted weighted average price per ADS of $0.8758. These ADSs were purchased in multiple transactions at prices ranging from $0.84 to $0.90 per ADS, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.